Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma.
Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P.
N Engl J Med. 2009 Oct 22;361(17):1662-70.PMID: 19846851 [PubMed - indexed for MEDLINE]Related articles